Area Riservata
2001 / 2026, un anniversario per la ricerca

25 anni di ricerca sul tumore della mammella

Nel 2026 il Gruppo Italiano Mammella celebra 25 anni di attività nella ricerca scientifica e clinica sul tumore della mammella.

Il Congresso GIM 2026
La nostra ricerca

Principali pubblicazioni GIM

  • GIM9-NEO-ADIXERNOncologist / 2013
  • GIM2The Lancet / 2015
  • GIM6-PROMISEJAMA / 2015
  • GIM3-FATAThe Lancet Oncology / 2018
  • GIM4-LEADThe Lancet Oncology / 2021
  • GIM2The Lancet Oncology / 2022
  • GIM21-LiqERBceptJECCR / 2024
  • GIM12-TYPHEROncologist / 2025

Ricerca clinica e collaborazione scientifica

Il nostro impegno nella ricerca sul tumore della mammella

Il Gruppo Italiano Mammella (GIM) promuove, coordina e sostiene la ricerca scientifica, clinica e traslazionale in oncologia mammaria, ponendosi come punto di riferimento nazionale e internazionale per l’innovazione terapeutica e l’eccellenza scientifica.

Scopri la ricerca
  • Sviluppo di studi clinici e traslazionali
    Progettazione e conduzione di trial clinici focalizzati sia sull'efficacia di nuove molecole e terapie target, sia sulla ricerca biologica e di biomarcatori predittivi.
  • Collaborazione e network scientifico
    Creazione di sinergie tra ricercatori, centri oncologici d'eccellenza, IRCCS, istituzioni accademiche e gruppi di cooperazione internazionali per facilitare studi multicentrici ad alto impatto.
  • Medicina di precisione e profilazione genomica
    Sviluppo e validazione di strategie di trattamento personalizzate basate sulle caratteristiche molecolari del tumore, con l'obiettivo di ottimizzare l'efficacia dei farmaci e ridurre la tossicità.
  • Digital Health, Big Data e Real World Evidence
    Sviluppo dei registri di patologia e utilizzo dei dati di vita reale (Real-World Data) per monitorare l'efficacia dei trattamenti a lungo termine e guidare le scelte di sanità pubblica.

Il tumore della mammella in Italia

Una delle principali sfide della ricerca oncologica

Il carcinoma della mammella è il tumore più frequentemente diagnosticato nelle donne in Italia. I progressi nella diagnosi precoce, nella caratterizzazione della malattia e nelle strategie terapeutiche hanno contribuito al miglioramento della prognosi. L’elevato numero di nuove diagnosi conferma tuttavia l’importanza della ricerca clinica e della collaborazione scientifica.

Nuove diagnosi stimate nel 2024
0
Sopravvivenza netta a 5 anni
0 %
Donne viventi dopo una diagnosi
0

Fonte: AIOM, AIRTUM et al. I numeri del cancro in Italia 2025.
I dati riportati si riferiscono agli anni indicati nelle stime disponibili.

STUDI CLINICI

Gli studi clinici progettati dal Gruppo GIM

Tutti gli studi clinici
  • Studi in fase di start-up
GIM46

Stadio avanzato / metastatico

MAGNETIC2

Studio di fattibilità di un approccio di monitoraggio dinamico sostenibile, adattato al rischio e strutturato su due livelli, per lo switch della terapia endocrina guidato dalla mutazione di ESR1 nel carcinoma mammario metastatico HR+/HER2− in prima linea.

Scopri lo studio
GIM45

Stadio avanzato / metastatico

SPARK

Impatto del GnRH analogo sulla soppressione ovarica in pazienti premenopausali affette da carcinoma mammario avanzato HR-positivo/HER2-negativo trattate con inibitori dell’aromatasi e inibitori di CDK4/6.

Scopri lo studio
GIM44

Fase precoce

MATISSE

Studio di fase III di non inferiorità per valutare l’omissione della chemioterapia adiuvante in pazienti con carcinoma mammario in stadio precoce, ad alto rischio, recettori ormonali positivo/HER2-negativo candidate ad abemaciclib adiuvante.

Scopri lo studio
GIM42

Fase precoce

NEOELA

Terapia neoadiuvante con elacestrant nel carcinoma mammario lobulare localmente avanzato: studio NEOELA.

Scopri lo studio
  • Studi clinici attivati
GIM35

Stadio avanzato / metastatico

RIBOSIL

Prevenzione dell’epatotossicità correlata a ribociclib in pazienti con carcinoma mammario: studio di fase II, multicentrico, in aperto, a braccio singolo, con sylimarin.

Scopri lo studio
GIM33

Stadio avanzato / metastatico

TRUTH

Efficacia di Trastuzumab-Deruxtecan (T-DXd) nel trattamento del carcinoma mammario metastatico (MBC) HER2-positivo nelle prime linee di trattamento: analisi retrospettiva di pratica clinica reale su pazienti trattati in Italia.

Scopri lo studio
GIM32

Fase precoce

PERSEVERE-X

Beneficio della terapia adiuvante nel carcinoma mammario in pazienti in premenopausa in funzione del test OncotypE DX.

Scopri lo studio
GIM31

Fase precoce

Neo-AGILE

Studio neoadiuvante con Abemaciclib e GIredestrant in pazienti con carcinoma mammario in fase iniziale ER-positivo e HER2-negativo.

Scopri lo studio
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

MEETING ED EVENTI

Congresso GIM 2026: la Riunione Annuale dei 25 anni

A Genova la Riunione Annuale del Gruppo Italiano Mammella ha celebrato i 25 anni di attività del GIM, con l’aggiornamento sugli studi in corso, le nuove proposte di ricerca e il confronto sui principali avanzamenti nei setting luminale, HER2-positivo e triplo negativo.
Ci vediamo a Roma per la prossima Riunione Annuale GIM.

  • Data

4 e 5 settembre 2026

  • Luogo

Hotel NH Collection Genova Marina
Molo Ponte Calvi 5, Genova

  • Responsabile scientifico

Lucia Del Mastro

  • Comitato organizzatore

Grazia Arpino, Michelino De Laurentiis, Alessandra Fabi, Fabio Puglisi

Il corso ha ottenuto 5,6 crediti ECM per Medici Chirurghi specializzati in Oncologia.

Visualizza slide
Consulta il programma completo

RIUNIONE GIM

Genova, 4 e 5 Settembre 2026

01
02
03
04
05
06
07
08

Centri GIM

Una rete di centri clinici in tutta Italia

Gli studi promossi dal Gruppo Italiano Mammella si svolgono in strutture ospedaliere, istituti di ricerca e centri oncologici distribuiti su tutto il territorio nazionale.

La collaborazione tra questi centri permette di arruolare le pazienti in tempi rapidi, di condividere competenze e metodologie e di rendere la ricerca clinica indipendente accessibile in ogni regione.

Seleziona un centro sulla mappa per consultarne i riferimenti.

Scopri i progetti di ricerca
0 centri in Italia

Seleziona un centro sulla mappa

NOTIZIE

News e pubblicazioni

Vai alle pubblicazioni
Tutte le News

Competenze e collaborazione scientifica

Una rete di professionisti per la ricerca in oncologia mammaria

Il Gruppo Italiano Mammella (GIM) promuove la collaborazione tra professionisti impegnati nella ricerca scientifica e clinica, favorendo il confronto e la condivisione delle competenze nell’ambito dell’oncologia mammaria.

Medici, ricercatori e professionisti della ricerca clinica contribuiscono allo sviluppo di iniziative scientifiche, formative e collaborative finalizzate al progresso delle conoscenze e al miglioramento della ricerca sul tumore della mammella.

Scopri GIM

ISCRIVITI

Diventa socio GIM

Entra a far parte del Gruppo Italiano Mammella e contribuisci alle attività scientifiche, formative e collaborative dell’Associazione dedicate alla ricerca oncologica, con particolare attenzione al tumore della mammella.

L’adesione a GIM è gratuita e non prevede il versamento di quote associative annuali.

Iscriviti ora